Neurotronic Announces Presentation of First Clinical Outcomes of Multi‑Organ Denervation for Type 2 Diabetes and Hypertension
Groundbreaking results from two NECTAR trials were presented at TCT 2025 SAN FRANCISCO, Oct. 27, 2025 /PRNewswire/ — Neurotronic, Inc., a developer of multi-organ denervation to treat complex cardiovascular and metabolic disease,…